文献速递肝病

他汀类药物使用对非酒精性脂肪性肝病发生与进展的影响:全国性巢式病例对照研究

Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

该研究基于韩国国家健康信息数据库2010年录入并随访至2016年的11,593,409名受试者,采用巢式病例对照设计,以脂肪肝指数(FLI)诊断NAFLD、以BARD评分评估显著肝纤维化。结果显示他汀使用与NAFLD发生风险降低相关(AOR 0.66;95%CI 0.65-0.67),并与显著肝纤维化风险降低相关(AOR 0.43;95%CI 0.42-0.44),且独立于糖尿病。

要点

  • 他汀使用与NAFLD发生风险降低相关,校正后OR为0.66(95%CI 0.65-0.67)。
  • 他汀使用与显著肝纤维化风险降低相关,校正后OR为0.43(95%CI 0.42-0.44)。
  • 上述关联独立于糖尿病:合并糖尿病者NAFLD发生AOR 0.44、无糖尿病者0.71。

核心结论

  • 在这项大型人群研究中,他汀使用降低了NAFLD发生风险以及NAFLD发生后肝纤维化的风险。

研究设计与样本

  • 全国性巢式病例对照研究,纳入韩国国家健康信息数据库2010年录入并随访至2016年的11,593,409名受试者。
  • NAFLD通过计算脂肪肝指数(FLI)诊断,显著肝纤维化通过BARD评分评估。
  • 对照按1:5比例从选择时点有成为病例风险的个体中随机选取。

主要发现

  • 在FLI<30的非NAFLD队列5,339,901名受试者中,最终有164,856名发生NAFLD。
  • 他汀使用与NAFLD发生风险降低相关(AOR 0.66;95%CI 0.65-0.67),且独立于糖尿病(合并糖尿病:AOR 0.44;95%CI 0.41-0.46;无糖尿病:AOR 0.71;95%CI 0.69-0.72)。
  • 在FLI>60的NAFLD队列712,262名受试者中,111,257名BARD评分≥2并被定义为肝纤维化病例。
  • 他汀使用降低显著肝纤维化风险(AOR 0.43;95%CI 0.42-0.44),独立于糖尿病(合并糖尿病:AOR 0.31;95%CI 0.31-0.32;无糖尿病:AOR 0.52;95%CI 0.51-0.52)。

关键数值与推荐

  • NAFLD诊断标准为脂肪肝指数(FLI)<30(非NAFLD队列)或>60(NAFLD队列)。
  • 显著肝纤维化定义为BARD评分≥2。
  • 他汀使用与NAFLD发生风险降低相关(AOR 0.66;95%CI 0.65-0.67)。
  • 他汀使用与显著肝纤维化风险降低相关(AOR 0.43;95%CI 0.42-0.44)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The use of statins in nonalcoholic fatty liver disease (NAFLD) may reduce cardiovascular morbidity, although their effect on NAFLD itself is not well known. We aimed to investigate the role of statins on the development of de novo NAFLD and progression of significant liver fibrosis. METHODS: This study included 11,593,409 subjects from the National Health Information Database of the Republic of Korea entered in 2010 and followed up until 2016. NAFLD was diagnosed by calculating fatty liver index (FLI), and significant liver fibrosis was evaluated using the BARD score. Controls were randomly selected at a ratio of 1:5 from individuals who were at risk of becoming the case subjects at the time of selection. RESULTS: Among 5,339,901 subjects that had a FLI < 30 and included in the non-NAFLD cohort, 164,856 subjects eventually had NAFLD developed. The use of statin was associated with a reduced risk of NAFLD development (adjusted odds ratio [AOR] 0.66; 95% confidence interval [CI] 0.65-0.67) and was independent of associated diabetes mellitus (DM) (with DM: AOR 0.44; 95% CI 0.41-0.46, without DM: AOR 0.71; 95% CI 0.69-0.72). From 712,262 subjects with a FLI > 60 and selected in the NAFLD cohort, 111,257 subjects showed a BARD score ≥ 2 and were defined as liver fibrosis cases. The use of statins reduced the risk of significant liver fibrosis (AOR 0.43; 95% CI 0.42-0.44), independent of DM (with DM: AOR 0.31; 95% CI 0.31-0.32, without DM: AOR 0.52; 95% CI 0.51-0.52). DISCUSSION: In this large population-based study, statin use decreased the risk of NAFLD occurrence and the risk of liver fibrosis once NAFLD developed.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Lee JI, Lee HW, Lee KS, et al. Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. Am J Gastroenterol. 2021. PMID: 33027082. doi:10.14309/ajg.0000000000000845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。